News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Day In Review: Urigen Inc. Uses Valentis, Inc. (VLTS) For Reverse Merger


10/6/2006 6:07:58 PM

October 6, 2006 -- Valentis will be bought as part of a reverse merger by privately held Urigen; Wyeth filed for marketing approval of a renal cell carcinoma drug in the US and Europe; Schering-Plough won marketing approval in Europe for Suboxone, a treatment for opioid dependence; deCODE genetics is suspending a trial of an anti-heart attack medication because of a manufacturing problem; Chattem bought US rights to five leading OTC medications from Johnson & Johnson; and Genta completed a Special Protocol Assessment with the FDA for Genasense. The Centient Biotech 200™ rose a fraction of a point to 3898.09, a positive move of just .01%. More details...

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES